Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07818018 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

Name: A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT07818018)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorMemorial Sloan Kettering Cancer Center

Started2026-09-04

View on ClinicalTrials.gov ↗

Memorial Sloan Kettering Cancer Center

779 trials monitored

See 100 trials at risk

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

Trial Details

NCT Number	NCT07818018
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Rockefeller University
Conditions	Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer
Enrollment	30 participants
Start Date	2026-09-04
Primary Completion	2029-09-04 (estimated)
Study Completion	2029-09-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-14